Literature DB >> 6828738

Irradiation of para-aortic lymph node metastases from carcinoma of the cervix or endometrium. Preliminary results.

R Komaki, R F Mattingly, R G Hoffman, S W Barber, R Satre, M Greenberg.   

Abstract

Twenty-two patients with biopsy-proved para-aortic lymph node metastases from carcinoma of the cervix (15 patients) or endometrium (7 patients) received a median dose of 5,000 rad/25 fractions. Para-aortic nodal metastases were controlled in 77% of cases. Control was significantly lower following radical retroperitoneal lymph node dissection than less extensive sampling procedures. Obstruction of the small bowel developed in 3 patients with tumor recurrence in the para-aortic region. Eight of the 10 patients who were disease-free at 2 years received greater than 5,000 rad. Three patients were still alive without disease at 129, 63, and 60 months, respectively. The 5-year disease-free survival rate was 40% for cervical cancer and 60% for endometrial cancer: in the former group, it was significantly different depending on whether the para-aortic nodes were irradiated (40%) or not (0%). The authors suggest that 5,000-5,500 rad in 5-5.5 weeks is well tolerated and can control aortic nodal metastases in cervical and possibly endometrial cancer.

Entities:  

Mesh:

Year:  1983        PMID: 6828738     DOI: 10.1148/radiology.147.1.6828738

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy.

Authors:  T Onda; H Yoshikawa; K Mizutani; M Mishima; H Yokota; H Nagano; Y Ozaki; A Murakami; K Ueda; Y Taketani
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Lymphadenectomy and adjuvant therapy in endometrial carcinoma: role of adjuvant chemotherapy.

Authors:  I Otsuka; T Kubota; T Aso
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.